COMMUNIQUÉS West-GlobeNewswire

-
Capital increase of 11,380 shares (equivalent to approximately 0.06% of the existing shares) in Orphazyme A/S as a result of an issue of bonus shares to KLSDC and UCLB
29/01/2018 -
Pressure BioSciences, Inc. CEO, Ric Schumacher, Rejoins “Stock Day”, Very Optimistic About His Company’s Growth and Success in 2018 and Beyond
29/01/2018 -
ProCare Pain Solutions Publishes New Research Exploring Effects of Fibromyalgia on Chronic Pain Population
29/01/2018 -
Ossur Hf : Transactions in relation to share buyback program
29/01/2018 -
Forward Pharma Announces the Decision of the European Patent Office in the Opposition Proceedings for the EP2801355 Patent
29/01/2018 -
Scapa Healthcare Introduces Low Trauma Hydrocolloid Adhesive for Sensitive Skin Applications
29/01/2018 -
Menlo Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
29/01/2018 -
US Defense Reports Broad Travelan® Reactivity to 180 Pathogenic Bacteria Including Camylobacter and Shigella
29/01/2018 -
Advantis Corp Expanding Into Colorado, California Nears Packaging Capacity With New Machine; Pre Orders for New Sizes Escalate Quickly
29/01/2018 -
NYC Plastic Surgeon Cautions Against Winter Binge Tanning And Its Damaging Effects
29/01/2018 -
InstaLipo™ Reduces Stubborn Fat Non-Surgically!
29/01/2018 -
Ritter Pharmaceuticals Appoints Diane J. Plotkin as Vice President of Clinical Development, Ahead of the Launch of its Phase 3 Clinical Trial
29/01/2018 -
Innovation Pharmaceuticals Brilacidin Franchise Anchored in Three Clinical Indications — Oral Mucositis, Inflammatory Bowel Disease and Serious Skin Infections; Expands into Dermatologic Diseases
29/01/2018 -
Sun Biopharma, Inc. Announces Initiation of First-Line Combination Study of Sbp-101 With Gemcitabine and Nab-Paclitaxel in Patients With Pancreatic Cancer
29/01/2018 -
DiaMedica to Present at the 14th Annual Noble Investor Conference
29/01/2018 -
Abeona Receives FDA Regenerative Medicine Advanced Therapy Designation for EB-101 Gene Therapy in Epidermolysis Bullosa
29/01/2018 -
Hemispherx to Present at the BIO CEO & Investor Conference
29/01/2018 -
Adamas Announces Closing of Its Public Offering of Common Stock, and Full Exercise of Underwriters’ Option to Purchase Additional Shares
29/01/2018 -
Ultragenyx Appoints Camille L. Bedrosian, M.D. as Chief Medical Officer and Executive Vice President
29/01/2018
Pages